A new study reveals how C210, a curcumin derivative, selectively reactivates Epstein–Barr virus to kill cancer cells without infectious risks, paving the way for safer, targeted cancer therapies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback